• Home
  • About Us
  • News / Videos



October 15, 2013: Scleral crosslinking mimics age-related ocular rigidity

A new biomedical engineering model may provide more information about the impact of ocular rigidity on loss of accommodation and ultimately may become a model to demonstrate the mechanism of action of how reduced ocular rigidity could facilitate more control over ocular accommodation in humans.

The Laser Anterior Ciliary Excision (LaserACE®) procedure (Ace Vision Group) uses a laser to create matrices of micropores in the sclera over the ciliary muscle complex. The group performed a pilot study that showed the impact of this novel procedure on ocular rigidity.

Read Full Article

February 2008: Illuminating LaserACE®

For some ophthalmologists, the holy grail of presbyopia correction lies in restoring the eye’s natural accommodative ability. A new procedure, LaserACE (Ace Vision Group, Inc., Silver Lake, Ohio), makes a compelling attempt to do just that. The technology, which has been six years in the making, employs a new device, the VisioLite ER:YAG Ophthalmic Laser System, used to ablate scleral tissue in an effort to restore elastic mobility and improve lens deformation.

Read Full Article

February 13, 2008: LaserACE® presbyopia procedure shows stable results over time.

BARCELONA — Long-term results with up to 4 years follow-up show that the LaserACE® presbyopia correction procedure can restore accommodation in a safe, effective and stable manner, according to a surgeon speaking here.

“Patients regain 2 D to 3 D of accommodation and do not appear to lose [it] over time,” Dimitrii Dementiev, MD, said at the winter meeting of the European Society of Cataract and Refractive Surgeons.

The procedure uses a 2.94 µm Er:YAG laser to create 600 µm microexcisions that lead to the decompression of connective tissue in three critical zones of the sclera. This simple and minimally invasive approach restores the physiological conditions necessary for the accommodative process, he said.

Read Full Article


Note: LaserACE® is not yet FDA approved or available in the United States. It is currently in clinical trials only in select areas outside of the United States.